Available Vaccines
Typhoid Fever
Introduction
Typhoid fever is a systemic infection caused by the gram-negative Salmonella enterica, subspecies enterica, serotype Typhi. Transmission is primarily via the oral route following ingestion of food or water contaminated by faeces and occasionally the urine of acutely ill persons or those who are chronic carriers. Direct faecal–oral transmission can also occur.
Following an incubation period of 10-20 days, clinical presentation range from mild fever, diarrhoea, myalgia and headache to severe disseminated disease with multi-organ involvement in 10-15% of cases. The case–fatality rate (CFR) is <1% with prompt antibiotic therapy, but may be as high as 20% in untreated or inappropriately treated cases.
Typhoid is also regarded as a travel-related disease with a considerably higher risk following travel to many developing areas of the WHO African, Eastern Mediterranean, South-east Asia and Western Pacific regions. In 2021, an estimated 9.3 million cases of enteric fever and 107,500 related deaths were reported worldwide, with South Asia bearing the highest burden.
Typhoid fever is endemic in Malaysia, with the incidence rate of typhoid and paratyphoid fever ranging from 0.20 to 0.55 per 100,000 population annually in recent years (2020–2024). The mortality rate during the same period was reported to be between 0.00-0.02 per 100,000 population. A recent outbreak of typhoid fever occurred in Kelantan in 2024.
Table 24.1 Vaccines Registered in Malaysia

Table 24.2 High-Risk Groups in Malaysia in Malaysia

Implications for Healthcare Workers (HCWs)
The vaccine is not routinely recommended for HCWs in non-endemic settings.
Evidence of Safety and Effectiveness
Based on pooled estimates from clinical trials and post-marketing surveillance data, local reactions (pain, swelling, erythema and induration at injection site) are the most commonly reported symptoms following Vi vaccine. Following Ty21a vaccine, the most reported adverse events are gastro-intestinal symptoms, nausea, fever and headache.
Based on four eligible studies in recent systematic review and meta-analysis in 2024, the oral vaccine Ty21a reduced the incidence of typhoid fever with vaccine efficacy of 45% at 1–3 years. The protection declines slightly over time with protection at 1–5 years post-vaccination at 43%.
In the same 2024 systematic review and meta-analysis evaluating the Vi-Polysaccharide Vaccine, the vaccine efficacy was 67% at 1 year and 56% at 2 years post-vaccination, whereas the pooled 1–3 years post-vaccination indicated efficacy of 58%.
References
- Piovani, D., Figlioli, G., Nikolopoulos, G.K., and Bonovas S. (2024). The global burden of enteric fever, 2017–2021: A systematic analysis from the Global Burden of Disease Study 2021. EClinicalMedicine, 77, https://doi.org/10.1016/j.eclinm.2024.102883
- Ministry of Health Malaysia. (2023). Health facts: Incidence rate and mortality rate of communicable diseases. https://www.moh.gov.my/moh/resources/Penerbitan/Penerbitan%20Utama/4._Health_Facts_2023-compressed_.pd
- World Health Organization. (March 30, 2023). https://www.who.int/news-room/fact-sheets/detail/typhoid
- World Health Organization. (March 30, 2018). Typhoid vaccines: WHO position paper, March 2018. Weekly Epidemiological Record, 93:153–172. https://www.who.int/publications/i/item/typhoid-vaccines-who-position-paper-march-2018
- Centers for Disease Control and Prevention. (April 23, 2025).Typhoid and Paratyphoid Fever. In CDC Yellow Book 2026: Health Information for International Travel. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/typhoid-and-paratyphoid-fever.html
- Vivotif. (2025). Typhoid vaccine live oral Ty21a: Prescription information. https://vivotif.com/
- Batool, R., Haq Qamar, Z., Abdus Salam, R., Yousafzai, M.T., Ashorn, P., & Naz Qamar, F. (2024). Efficacy of typhoid vaccines against culture-confirmed Salmonella typhi in typhoid-endemic countries: A systematic review and meta-analysis. The Lancet Global Health, 12(4), e589–e598. https://doi.org/10.1016/S2214-109X(23)00606-X
- Ministry of Health Malaysia. (2025). Malaysian National Centre of Adverse Drug Reactions database. https://npra.gov.my